CGEN
Compugen Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.49
+1.22%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.47
From 52W high−19.68%
Volume127601.00
Market cap$235.87M
P/E (TTM)6.6x
P/S (TTM)3.2x
Div yield—
Key dataSep 18, 2026
Open
$2.47
From 52W high
−19.68%
Volume
127601.00
Market cap
$235.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
3.2x
P/E (TTM)
6.6x
RSI (14)
46.9
MomentumView details →
1D Return
+1.22%
YTD Return
+60.46%
SummaryUpdated Jun 1, 2026
Compugen Ltd. (NASDAQ:CGEN) is an Israeli clinical-stage biotechnology company founded in 1993 and headquartered in Holon, Israel. The company went public in 2000 and has evolved from its origins in computational biology to become a focused immuno-oncology drug developer. Compugen utilizes its proprietary computational discovery platform to identify novel immune checkpoint targets and develops therapeutic antibodies to treat cancer patients. The company has established strategic partnerships with major pharmaceutical companies including AstraZeneca, Bayer, and Gilead Sciences to advance its pipeline of innovative cancer treatments.
Similar companies
Latest newsMore news →